Human and rat mesangial cell receptors for glucose-modified proteins: potential role in kidney tissue remodelling and diabetic nephropathy

doi:10.1084/jem.174.4.931

This Article

	Full Text (PDF, 1083K)
	Alert me when this article is cited
	Citation Map

Services

	Email this article
	Similar articles in this journal
	Similar articles in PubMed
	Alert me to new content in the JEM
	Download to citation manager

Citing Articles

	Citing Articles via HighWire
	Citing Articles via CrossRef
	Citing Articles via Google Scholar

Google Scholar

	Articles by Skolnik, E. Y.
	Articles by Vlassara, H.
	Search for Related Content

PubMed

	PubMed Citation
	Articles by Skolnik, E. Y.
	Articles by Vlassara, H.


Social Bookmarking

	What's this?

ARTICLES

Human and rat mesangial cell receptors for glucose-modified proteins: potential role in kidney tissue remodelling and diabetic nephropathy

EY Skolnik, Z Yang, Z Makita, S Radoff, M Kirstein and H Vlassara
Laboratory of Medical Biochemistry, Rockefeller University, New York, New York 10021.

Advanced glycosylation endproducts (AGEs) are derived from the nonenzymatic addition of glucose to proteins. AGEs have been found to accumulate on tissue proteins in patients with diabetes, and their accumulation is thought to play a role in the development of diabetic complications. The finding that macrophages and endothelial cells contain AGE-specific receptors led us to examine whether mesangial cells (MCs) also possess a mechanism for recognizing and processing AGEs. Membrane extracts isolated from rat and human MCs were found to bind AGE-bovine serum albumin (BSA) in a saturable fashion, with a binding affinity of 2.0 +/- 0.4 x 10(6) M-1 (500 nM). The binding was specific for the AGE adduct, since AGE-modified collagen I and ribonuclease both competitively inhibited 125I-AGE-BSA binding to MC membranes, while the unmodified proteins did not compete. Binding of AGE proteins was followed by slow internalization and degradation of the ligand. Ligand blotting of MC membrane extracts demonstrated three distinct AGE-binding membrane proteins of 50, 40, and 30 kD. Growth of MCs on various AGE-modified matrix proteins resulted in alterations in MC function, as demonstrated by enhanced production of fibronectin and decreased proliferation. These results point to the potential role that the interaction of AGE-modified proteins with MCs may play in vivo in promoting diabetic kidney disease.
Add to CiteULike CiteULike Add to Complore Complore Add to Connotea Connotea Add to Del.icio.us Del.icio.us Add to Digg Digg Facebook Add to Reddit Reddit Add to Technorati Technorati Twitter What's this?

This article has been cited by other articles:

Pozzi, A., Zent, R., Chetyrkin, S., Borza, C., Bulus, N., Chuang, P., Chen, D., Hudson, B., Voziyan, P. (2009). Modification of Collagen IV by Glucose or Methylglyoxal Alters Distinct Mesangial Cell Functions. J. Am. Soc. Nephrol. 20: 2119-2125 [Abstract] [Full Text]
Qian, Y., Feldman, E., Pennathur, S., Kretzler, M., Brosius, F. C. III (2008). From Fibrosis to Sclerosis: Mechanisms of Glomerulosclerosis in Diabetic Nephropathy. Diabetes 57: 1439-1445 [Full Text]
Nasr, S. H., D'Agati, V. D. (2007). Nodular Glomerulosclerosis in the Nondiabetic Smoker. J. Am. Soc. Nephrol. 18: 2032-2036 [Abstract] [Full Text]
Huebschmann, A. G., Regensteiner, J. G., Vlassara, H., Reusch, J. E.B. (2006). Diabetes and Advanced Glycoxidation End Products.. Diabetes Care 29: 1420-1432 [Full Text]
Galkina, E., Ley, K. (2006). Leukocyte Recruitment and Vascular Injury in Diabetic Nephropathy. J. Am. Soc. Nephrol. 17: 368-377 [Abstract] [Full Text]
Brownlee, M. (2005). The Pathobiology of Diabetic Complications: A Unifying Mechanism. Diabetes 54: 1615-1625 [Full Text]
Schrijvers, B. F., De Vriese, A. S., Flyvbjerg, A. (2004). From Hyperglycemia to Diabetic Kidney Disease: The Role of Metabolic, Hemodynamic, Intracellular Factors and Growth Factors/Cytokines. Endocr. Rev. 25: 971-1010 [Abstract] [Full Text]
Lu, C., He, J. C., Cai, W., Liu, H., Zhu, L., Vlassara, H. (2004). Advanced glycation endproduct (AGE) receptor 1 is a negative regulator of the inflammatory response to AGE in mesangial cells. Proc. Natl. Acad. Sci. USA 101: 11767-11772 [Abstract] [Full Text]
Santana, R. B., Xu, L., Chase, H. B., Amar, S., Graves, D. T., Trackman, P. C. (2003). A Role for Advanced Glycation End Products in Diminished Bone Healing in Type 1 Diabetes. Diabetes 52: 1502-1510 [Abstract] [Full Text]
Hou, F. F., Jiang, J. P., Guo, J. Q., Wang, G. B., Zhang, X., Stern, D. M., Schmidt, A. M., Owen, W. F. Jr. (2002). Receptor for Advanced Glycation End Products on Human Synovial Fibroblasts: Role in the Pathogenesis of Dialysis-Related Amyloidosis. J. Am. Soc. Nephrol. 13: 1296-1306 [Abstract] [Full Text]
TANJI, N., MARKOWITZ, G. S., FU, C., KISLINGER, T., TAGUCHI, A., PISCHETSRIEDER, M., STERN, D., SCHMIDT, A. M., D'AGATI, V. D. (2000). Expression of Advanced Glycation End Products and Their Cellular Receptor RAGE in Diabetic Nephropathy and Nondiabetic Renal Disease. J. Am. Soc. Nephrol. 11: 1656-1666 [Abstract] [Full Text]
Matsubara, Y., Murata, M., Maruyama, T., Handa, M., Yamagata, N., Watanabe, G., Saruta, T., Ikeda, Y. (2000). Association between diabetic retinopathy and genetic variations in alpha 2beta 1 integrin, a platelet receptor for collagen. Blood 95: 1560-1564 [Abstract] [Full Text]
MENÈ, P., PASCALE, C., TETI, A., BERNARDINI, S., CINOTTI, G. A., PUGLIESE, F. (1999). Effects of Advanced Glycation End Products on Cytosolic Ca2+ Signaling of Cultured Human Mesangial Cells. J. Am. Soc. Nephrol. 10: 1478-1486 [Abstract] [Full Text]
SUZUKI, D., MIYATA, T., SAOTOME, N., HORIE, K., INAGI, R., YASUDA, Y., UCHIDA, K., IZUHARA, Y., YAGAME, M., SAKAI, H., KUROKAWA, K. (1999). Immunohistochemical Evidence for an Increased Oxidative Stress and Carbonyl Modification of Proteins in Diabetic Glomerular Lesions. J. Am. Soc. Nephrol. 10: 822-832 [Abstract] [Full Text]
Wautier, J.-L., Guillausseau, P.-J. (1998). Diabetes, advanced glycation endproducts and vascular disease. Vasc Med 3: 131-137 [Abstract]
Bierhaus, A., Hofmann, M. A, Ziegler, R., Nawroth, P. P (1998). AGEs and their interaction with AGE-receptors in vascular disease and diabetes mellitus. I. The AGE concept. Cardiovasc Res 37: 586-600 [Abstract] [Full Text]
Corman, B., Duriez, M., Poitevin, P., Heudes, D., Bruneval, P., Tedgui, A., Levy, B. I. (1998). Aminoguanidine prevents age-related arterial stiffening and cardiac�hypertrophy. Proc. Natl. Acad. Sci. USA 95: 1301-1306 [Abstract] [Full Text]
Visona, A., Lusiani, L., Bonanome, A., Beltramello, G., Confortin, L., Papesso, B., Costa, F., Pagnan, A. (1995). Wall Thickening of Common Carotid Arteries in Patients Affected by Noninsulin-Dependent Diabetes Mellitus: Relationship to Microvascular Complications. ANGIOLOGY 46: 793-799 [Abstract]
Makita, Z, Vlassara, H, Rayfield, E, Cartwright, K, Friedman, E, Rodby, R, Cerami, A, Bucala, R (1992). Hemoglobin-AGE: a circulating marker of advanced glycosylation. Science 258: 651-653 [Abstract]
Ohgami, N., Nagai, R., Ikemoto, M., Arai, H., Kuniyasu, A., Horiuchi, S., Nakayama, H. (2001). CD36, a Member of the Class B Scavenger Receptor Family, as a Receptor for Advanced Glycation End Products. J. Biol. Chem. 276: 3195-3202 [Abstract] [Full Text]
Ohgami, N., Nagai, R., Miyazaki, A., Ikemoto, M., Arai, H., Horiuchi, S., Nakayama, H. (2001). Scavenger Receptor Class B Type I-mediated Reverse Cholesterol Transport Is Inhibited by Advanced Glycation End Products. J. Biol. Chem. 276: 13348-13355 [Abstract] [Full Text]